Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of FS-1502 in HER2-positive, RAS/BRAF wild-type metastatic colorectal cancer
CTR20220187Phase 2Terminated
- Sponsor
- Fosun Pharma
- Start
- Jan 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of caxmotabart entudotin in colorectal cancer (CRC), sponsored by Fosun Pharma. Started Jan 2022; status: terminated.
02
Drugs
caxmotabart entudotin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20220187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220187.